Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Am J Case Rep ; 18: 1325-1329, 2017 Dec 12.
Artículo en Inglés | MEDLINE | ID: mdl-29229899

RESUMEN

BACKGROUND Ellis-van Creveld syndrome is an autosomal recessive chondro-ectodermal dysplasia characterized by disproportionate short stature, limb shortening, narrow chest, postaxial polydactyly and dysplastic nails and teeth. In addition, 60% of cases present congenital heart defects. Ellis-van Creveld syndrome is predominantly caused by mutations in the EVC or EVC2 (4p16) genes, with only a few cases caused by mutations in WDR35.  CASE REPORT Here, we report on two Mexican families with patients diagnosed with Ellis-van Creveld syndrome. Family 1 includes four patients: three females of 15, 18, and 23 years of age and a 7-year old male. Family 2 has only one affected newborn male. All patients exhibited multiple features including hypodontia, dysplastic teeth, extra frenula, mild short stature, distal limb shortening, postaxial polydactyly of hands and feet, nail dystrophy, and knee joint abnormalities. Only two patients had an atrial septal defect. In all cases, molecular analysis by Sanger sequencing identified the same homozygous mutation in exon 12 of EVC, c.1678G>T, which leads to a premature stop codon.  CONCLUSIONS The mutation c.1678G>T has been previously reported in another Mexican patient and it appears to be a recurrent mutation in Mexico which could represent a founder mutation. The large number of patients in this case allows the clinical variability and spectrum of manifestations present in individuals with Ellis-van Creveld syndrome even if they carry the same homozygous mutation in a same family.


Asunto(s)
Codón sin Sentido , Síndrome de Ellis-Van Creveld/genética , Fenotipo , Proteínas/genética , Adolescente , Niño , Exones , Femenino , Homocigoto , Humanos , Recién Nacido , Masculino , Proteínas de la Membrana , México , Adulto Joven
2.
Eur J Nutr ; 52(3): 1157-67, 2013 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22832899

RESUMEN

PURPOSE: Folic acid (FA) is an emerging nutritional factor in the pathogenesis of diverse neurodegenerative disorders by still unknown mechanisms. The hippocampus is altered during the loss of cognitive abilities in humans and selectively affected when homocysteine increases. The aim was to evaluate the potential protective role of folic acid in the maintenance of biochemical markers related to the methionine cycle, as well as the integrity of the hippocampus as part of the brain in aged rats. METHODS: Male Sprague-Dawley rats (18 months old) were assigned to four different folic acid groups (0 mg FA/kg diet, deficient; 2 mg FA/kg diet, control; 8 mg FA/kg diet, moderate supplementation; 40 mg FA/kg diet, extra supplementation) for 30 days. We evaluated several parameters related to the methionine cycle. In addition, hippocampus areas were immunostained for specific neuronal markers and astrocytes. RESULTS: Serum folate levels increased according to FA dietary level (p < 0.01). There was a significant increase in the serum homocysteine concentrations in the folic acid-deficient diet group (p < 0.01). However, brain S-adenosylmethionine and S-adenosylhomocysteine did not differ significantly between the folic acid groups. Consequently, the methylation ratio was also unchanged. The morphometric analysis did not show any differences in the number of neurons and astrocytes between groups, except when comparing the folic acid-deficient diet versus folic acid-supplemented diet in the striatum of the hippocampus. CONCLUSIONS: Clearly, the dietary FA deficiency negatively affects the methionine metabolism biomarkers, while excessive supplementation seems to be unnecessary for optimal maintenance of the methylation cycle and hippocampus integrity.


Asunto(s)
Envejecimiento , Disfunción Cognitiva/prevención & control , Dieta , Ácido Fólico/uso terapéutico , Hipocampo/metabolismo , Metionina/metabolismo , Fármacos Neuroprotectores/uso terapéutico , Animales , Astrocitos/metabolismo , Astrocitos/patología , Biomarcadores/metabolismo , Disfunción Cognitiva/etiología , Disfunción Cognitiva/metabolismo , Disfunción Cognitiva/patología , Dieta/efectos adversos , Suplementos Dietéticos , Ácido Fólico/administración & dosificación , Ácido Fólico/sangre , Ácido Fólico/metabolismo , Deficiencia de Ácido Fólico/dietoterapia , Deficiencia de Ácido Fólico/etiología , Deficiencia de Ácido Fólico/fisiopatología , Hipocampo/patología , Hiperhomocisteinemia/etiología , Hiperhomocisteinemia/fisiopatología , Hiperhomocisteinemia/prevención & control , Masculino , Metilación , Neuronas/metabolismo , Neuronas/patología , Fármacos Neuroprotectores/administración & dosificación , Fármacos Neuroprotectores/sangre , Fármacos Neuroprotectores/metabolismo , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley , S-Adenosilhomocisteína/metabolismo , S-Adenosilmetionina/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA